AIM
PETX

Alambic Investment Management’s Aratana Therapeutics, Inc. PETX Stock Holding History

Alambic Investment Management’s Portfolio PETX Stock Details PETX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-65,000
Closed -$398K – 426
2018
Q4 		$398K Buy
+65,000
New +$397K 0.17% 185

Other funds holding PETX

BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
EC
Engaged Capital Newport Beach, California $303M AUM 2.09% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
JG
Jefferies Group New York $12B AUM 6.2% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
GAI
General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return
GPGA
Grandeur Peak Global Advisors Salt Lake City, Utah $427M AUM 39.14% 1-Year Est. Return
Impax Asset Management Group
Impax Asset Management Group London, United Kingdom $14.3B AUM 19.8% 1-Year Est. Return

Alambic Investment Management's PETX Position: Q1 2019 in Review

Alambic Investment Management sold out of Aratana Therapeutics, Inc. (PETX) in Q1 2019, closing a stake of 65,000 shares — an estimated $398K sold.

Alambic Investment Management first reported a position in PETX in Q4 2018 and held it in 1 quarter. The position peaked at $398K in Q4 2018. 104 funds tracked by Wall St. Rank hold PETX as of Q1 2019.

  • Alambic Investment Management reported no remaining Aratana Therapeutics, Inc. position as of Q1 2019 after selling out during the quarter.
  • Alambic Investment Management sold 65,000 Aratana Therapeutics, Inc. shares in Q1 2019, an estimated $398K.
  • Alambic Investment Management first reported a position in Aratana Therapeutics, Inc. in Q4 2018 and held it in 1 quarter.
  • Alambic Investment Management's Aratana Therapeutics, Inc. position peaked at $398K in Q4 2018.
  • 104 funds tracked by Wall St. Rank held Aratana Therapeutics, Inc. as of Q1 2019.

Based on Alambic Investment Management's 13F filing for Q1 2019, filed 9 May 2019.